Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis
C. Ertus, Lucie‐Marie Scailteux, Alain Lescoat, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 4, pp. 368-380
Closed Access | Times Cited: 18

Showing 18 citing articles:

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 919-932
Open Access | Times Cited: 19
Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis
Sizheng Steven Zhao, David R. Riley, Gema Hernandez, et al.
Clinical Therapeutics (2025)
Open Access | Times Cited: 2
Comparative safety of oral Janus kinase inhibitors and dupilumab in patients with atopic dermatitis: a population-based cohort study
Serena Yun‐Chen Tsai, Wanda Phipatanakul, Elena B. Hawryluk, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 5, pp. 1195-1203.e3
Closed Access | Times Cited: 8
Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis
Hyun Jin Yim, Tiffany Jean, Peck Y. Ong
Current Allergy and Asthma Reports (2024) Vol. 24, Iss. 5, pp. 289-301
Open Access | Times Cited: 4
Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta‐Analysis of Cardiovascular Safety
Roberta Dunn, Edouard Long, L. Gagnon, et al.
eJHaem (2025) Vol. 6, Iss. 1
Open Access
Atopic dermatitis is associated with an increased risk of cardiovascular diseases: A large-scale, propensity-matched US-based retrospective study
Henner Zirpel, Sascha Ständer, Alicja Frączek, et al.
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 11, pp. 1405-1412
Closed Access | Times Cited: 3
Efficacy and safety of radiofrequency in the treatment of hidradenitis suppurativa; a systematic review
Mohammad Ali Nilforoushzadeh, Nazila Heidari, Amirhossein Heidari, et al.
Lasers in Medical Science (2024) Vol. 39, Iss. 1
Closed Access | Times Cited: 3
Risk of Cardiovascular Disease and Cancer in Patients Initiating JAK Versus IL‐4/‐13 Inhibitors for Atopic Dermatitis
Sizheng Steven Zhao, Gema Hernandez, Uazman Alam
International Journal of Dermatology (2025)
Open Access
Micro- and Macrovascular Effects of Inflammation in Peripheral Artery Disease—Pathophysiology and Translational Therapeutic Approaches
Michael Poledniczek, Christoph Neumayer, Christoph Kopp, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2284-2284
Open Access | Times Cited: 8
Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses
Qingying He, Xin Xie, Qian Chen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Nonsteroidal Approaches for Atopic Dermatitis: A Clinical Update
Peter Ch’en, Peter Lio
Dermatitis (2024)
Closed Access | Times Cited: 1
JAK Inhibitors in Immune Regulation and Treatment of Vitiligo
Kewei Liu, Linyi Zhou, Meihui Shi, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 80, pp. 87-96
Closed Access | Times Cited: 1
JAK inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism
Yachar Dawudi, Samuel Benarroch, H. L. Helfer, et al.
Research and Practice in Thrombosis and Haemostasis (2024) Vol. 9, Iss. 1, pp. 102667-102667
Open Access | Times Cited: 1
Navigating the atopic dermatitis toolbox
Archana Samynathan, Jonathan I. Silverberg
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 3, pp. 337-343
Closed Access | Times Cited: 3
Not just another klass (JAK) of inhibitors for allergies
Wesley H. Brooks, Yves Renaudineau
Deleted Journal (2024) Vol. 1, pp. 100001-100001
Open Access
Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database
Yu Sun, Tao Xu, Suyan Zhu, et al.
Expert Opinion on Drug Safety (2024) Vol. 24, Iss. 2, pp. 233-239
Closed Access
Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy
J. Williams, Ryan Hum, Kira Rogers, et al.
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access
Janus Kinase (JAK) Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis (Eczema): Systematic Review and Network Meta-Analysis
Ming Liu, Ya Gao, Yuan Yuan, et al.
(2024)
Closed Access
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis
Sarah G. Bridgeman, Anna K. Martino, Lindsay C. Strowd
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 2153-2159
Closed Access
Page 1

Scroll to top